• The number of possible prognostic and diagnostic genes for cancers;
Introduction
Cancers are characterized by distinct patterns of mutation and gene expression, associated with different prognosis.
Prognostic expression signatures have been extensively identified and overall survival exhibits links to diverse biological processes. Uhlen et al summarized that shorter survival is associated with the upregulation of genes related to cell growth and the downregulation of genes related to cellular differentiation. 1 For breast cancer, the MammaPrint test, including 70 genes, is able to assess the benefit of chemotherapy. 2 Metastasis is a key factor in short survival. In digestive cancers, besides activation of the mitotic cell cycle, altered expression in the extracellular matrix is linked to poor prognosis. [3] [4] [5] A 64-gene signature is associated with metastasis for non-small cell lung carcinoma (NSCLC). 6 Inflammatory-related genes are also involved in prognosis in glioblastoma (GBM), 7 colorectal, and pancreatic cancers. 3, 4 Recently, an estimate of the risk of recurrence of colon cancer was shown to be provided by the total tumor-infiltrating T-cell count and the cytotoxic tumor-infiltrating T-cell count. 8 In acute myeloid leukemia (AML), the worst overall survival is associated with the expression of multidrug resistant genes. 9 Also, genes in the tumor microenvironment have a prognostic role for NSCLC.
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Cancer-associated mutations have also been extensively studied. Recently, 299 driver mutation genes were revealed. 11 The study confirmed that microsatellite instability was associated with an improved response to immune checkpoint therapy. 11 A model estimating the mutation load of 24 genes predicted the response to cancer immunotherapy with anti-CTLA-4 and anti-PD-1 treatments.
12
The present work focuses on two questions. Firstly, what are the independent prognostic genes for each cancer? The expression signatures in the literature are actually combinations of a set of genes. [2] [3] [4] [5] [6] [7] 10, 13 A single gene as a prognostic marker would facilitate the development of a clinical test. Although some independent prognostic genes have been identified, including the genes for PSA for prostate cancer, 14 microRNA-148a for bladder cancer, 15 telomerase for colorectal cancer, 16 KIAA1199 for NSCLC, 17 and CTHRC1 for gastric cancer, 18 a systems-level identification of an independent prognostic gene is still needed. We also noticed that the signature genes differ depending on the criteria. It will be interesting to discover which genes are identified under tighter criteria. Secondly, what are the links between expression of the prognostic genes and the mutations present for a specific cancer? Given that the mutations are the original driving factors for the tumor, 4 mutations to the altered gene expression, and how does the link determine the prognosis? We will explore the connection.
Here we revealed the independent overall survival-associated genes for each cancer type and identified the genes with capacities of both prognosis and diagnosis. The links between mutation and the prognostic gene expression were also investigated.
Materials and methods

Datasets
Gene expression data, survival data, and mutation data were retrieved from TCGA project from the initial release of Genomic Data Commons (GDC) in October 2016 using
RTCGAToolbox. 20 A total of 9523 samples across 29 tumor types were downloaded, including 8811 tumor tissues and 712 non-tumor tissues. The abbreviation for cancer type is in supplementary information. Microarray-based gene expression data (gene expression omnibus ID: GSE21501 for pancreatic cancer 21 ) were retrieved for validating.
Identification of the prognostic genes
The prognostic genes were identified with a log-rank test in a Kaplan-Meier survival model.
In each cancer type, for each gene, patients were classified into two groups, the high-expression group (H) and the low-expression group (L), using the expression median of the gene as a cutoff. In identifying, we considered both survival difference (P[SV]) and the expression change (FC(H/L)) between the two groups. The area under the curve (AUC) of a receiver operating characteristic (ROC) curve and the expression fold change between the cancer (C) and normal (N) tissues (FC(C/N)) were employed to indicate the diagnosis ability.
Regression for the expression of the prognostic genes with the mutation counts
The 40 prognostic genes, which were identified with P frequently mutated genes for each cancer type. The regression generated a set of parameters indicating the contribution of the mutation in explaining the expression level of the prognostic gene. Only mutated genes with a significant parameter were used to construct a network.
More details are in Supplementary Information.
Results
Prognostic genes differs across cancers
First, we found under the same cutoff of overall survival difference (P[SV]), the number of potential prognostic genes differed between cancer types (Fig. 1A and Fig. S1A ). Cancer CHOL, ESCA, STAD, COAD, GBM and PCPG had only a limited number of prognostic genes (Fig. 1A) . We assessed the diagnostic genes by calculating the area under the receiver operating characteristic (ROC) curve (AUC) between the cancer and control (normal) data.
The cancers also had different numbers of genes at a high AUC value (AUC≥0.9) (Fig. 1A) .
The result suggests that the number of prognostic and diagnostic genes differs between cancers.
We did not observe a link between the number of prognostic genes and the survival probability (Fig. 1B) . We calculated Pearson correlation coefficients (PCCs) of the gene expression of 25,301 genes for each pair of patients for each cancer, and associated the coefficients to the five-year survival probability. Interestingly, the survival probability highly correlated to the standard deviation (Std) of the PCC (r=−0.97) (Fig. 1C) .
The pathways and gene ontology (GO) terms that were enriched for the survival-related genes exhibited distinct clusters for the cancer types (Fig. 1D ). In KIRP, ACC, and MESO, the genes were enriched for the terms "cell cycle" and "cell division". CESC, BRCA, STAD, BLCA, and HNSC shared enriched term "T cell costimulation". LUSC, THCA, DBLC, UCEC, USC, and LIHC had common terms of "cell adhesion". GBM, LAML, and PAAD were not included in any of the clusters mentioned above. We observed a substantial enrichment in the term "Glycoprotein". P-glycoprotein was found in the multidrug resistance (MDR) phenotype of adult solid tumors. 22 The enrichment for the genes whose expressions change greatly is shown in Fig. S1B .
Prognostic genes identified
Then, we identified the prognostic genes. We considered two factors to be important. The first was a tight association between the variation of clinical outcome (here, overall survival) and Fig. 2A) . The genes CDC20, CDCA8, and CEP55 were prognostic in more than three cancer types. Other genes were specific for particular cancers, such as MYEOV for PAAD. Most of the genes had a hazard effect, meaning that high expression of the gene was associated with poorer overall survival ( Fig. 2A) . The prognostic genes were enriched for the terms of cell cycle, cell division, and cytoskeleton ( Fig.   S2 C and D). Moreover, in the space of the principal components (PCs) constructed with expression of the 40 genes, the cancer tissues showed clustering patterns and cancer types could be discriminated (Fig. 2B) , indicating that the genes represent cancer-type specific survival information.
As few prognostic genes were identified for some cancer types with the strict criteria ( Fig.   2A ), another strategy, using the Pearson correlation coefficient between survival time and gene expression, was applied to identify optional candidates from the 236 prognostic genes.
The result is shown in Fig. 2C . Although some of these genes are not in the list in Fig. 2A , they performed well in indicating survival, for instance, HIST3H2A and LRRC61 for GBM, and CA11 for PAAD ( Fig. 2C and D) .
Some of the prognostic genes have been previously identified. For instance, lower expression of MYBL2 is associated with a favorable overall survival in LGG, 25 LIHC, 26 and NSCLC. 7 High DKK1 was identified for gastric cancer. 28 NPTX2 has been suggested to have prognostic value for GBM, 29 we found it was moderately significant (p ≤ 0.05) for survival. 30 We also randomly selected one gene, MYEOV, and tested its prognostic performance with microarray-based data for PAAD (Fig. S2E ).
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Genes with prognostic and diagnostic capacities
We noticed that although some of the genes have prognostic abilities, their average expression levels are even higher in normal tissue than in the low-expression cancer tissues, which leads to confusion in predicting clinical outcome because there is a difficulty in deciding if an unknown tissue is cancer. An example is from gene DKK1 for LUAD (Fig. S3 ).
Therefore, we assessed the diagnostic ability of the 236 prognostic genes from two aspects. is a well-known prognostic predictor. 33 KIF14 is involved in many processes, including chromosome segregation and mitotic spindle formation.
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We also tested the possibility of fifteen immunoregulation-related genes in prognosis as well as diagnosis (Fig. 4) . PVR was significant for prognosis for KIRC and HNSC. The product of PVR is the ligand of TIGIT, which can repress the activity of NK cells. 8 value for BRCA (Fig. 4) .
Briefly, we identified 22 genes that have both prognostic and diagnostic capacities.
Links between mutations and prognostic genes
Finally, we investigated the association between the mutations and the expression of the prognostic genes. The genes with mutations were identified ( Fig. S6A and B) . The total mutations did not seem to be directly associated with survival ( Fig. S6C) . We normalized the mutation rate by dividing by gene length, as a longer gene has more chances to mutate.
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Interestingly, we found that genes with ~1 mutation per kbp had the lowest expression, in both cancer and control samples (Fig. S6D) . Additional analysis is shown in Fig. S7 .
We revealed the link between the mutated pathway and the expression of the prognostic genes ( Fig. 5A ). The prognostic genes could be placed in three classes. In the first class, the gene expression was affected by many mutated pathways in more than five cancer types. These genes were CDC20, CDCA8, ASPM, ERCC6L, KLRA1, KIF14, SGOL1, and FAM72D. We noticed CDC20, ERCC6L, ASPM, and CDCA8 are related to anaphase spindle assembly. 31,32,38,39 The second class included the genes whose expression was affected by only a few pathways, such "Focal adhesion", the "FoxO and ErbB signaling pathways" and "Carbohydrate digestion and absorption". These genes included GTS1, C1orf88, C5orf32, ATP6V1C2, CLIP, and C1QTNF6. In the last class, links were found to less than three cancer types, showing specificity. The genes MYEOV, ANKRD56, and C7orf29 are connected to mutations in the "Tight junction" and "Long-term potentiation" pathways. Mutations occurring in the PI3K/PI4K domain, methylation-related and central carbon metabolism-related genes showed extensive alteration of the expression levels of the prognostic genes.
We then tested the relationships between the mutated genes and the prognostic genes ( Fig.   5B ). CDC20, CDCA8, and ASPM were associated with a greater number of mutated genes.
Mutations in PKHD1, ATM, and ZNF536 were associated with a greater number of prognostic genes.
Frequently mutated genes, including TP53 and PTEN, showed a strong association to CDC20 expression ( Fig. 5B , Fig. 2A ). Mutations in TG (thyroglobulin), EP400, a component of the NuA4 histone acetyltransferase complex, and SI (a sucrase-isomaltase enzyme) showed links with CDCA8. Mutations in CNTNAP5, which encodes a cell adhesion molecule in the nervous system, 40 and mutations in ATM, whose product belongs to the PI3/PI4-kinase family and functions as a cell cycle checkpoint kinase, exhibited a link to the prognostic gene ASPM.
GTSE1 encodes a protein that is involved in p53-induced cell cycle arrest in G2/M phase by interfering with microtubule rearrangements. 41 We found that mutations in cadherin 23 (CDH23), which helps cells stick together, and TEX15, which is involved in DNA double-stranded break repair, are linked to GTSE1 expression. The expression of MYEOV is mainly affected by mutations in genes associated with intraflagellar transport (DYNC2H1), actin-microtubule interactions and cellular junctions (MACF1), myotendinous junctions (COL22A1), and calcium-binding microfibrils and glucose homeostasis (FBN1).
Briefly, we have provided an insight into the relationships between prognostic genes and genes mutated in cancers.
Discussion
Prognostic genes are important in estimating low-risk patients, assessing cancer progression, subtyping cancer, and making a proper plan for medical treatment. Here, we reveal the prognostic genes for overall survival for 29 cancers by systematic scanning.
Three points are highlighted. Firstly, the prognostic genes vary greatly among the cancer types.
It seems that the more subtypes the cancer has, the fewer prognostic genes. For instance, GBM can be classified into six subgroups (IDH, K27, G34, RTK I and II, and MES). 42 Breast tumors have five molecular subtypes (Luminal A, Luminal B, Her2 overexpressing, basal, and normal-like). 43 ESCA includes four subtypes. 44 The three cancers had fewer prognostic genes ( Fig. 1A-B) . In the literature, high levels of intratumor genetic heterogeneity are associated with poorer survival across cancers. 45 We found a significant association between the intertumor expression heterogeneity and the overall survival (Fig. 1C) .
Secondly, the 236 prognostic genes were identified under the criteria of both survival difference and expression change. Expression differentiation between cancer and adjacent normal tissues has been proven to be irrelevant to survival. 46 We demonstrated it is not appropriate to identify prognostic genes by comparing gene expression between cancer and control samples (DKK1, Fig. S3 ). 46 We identified 22 genes for both prognosis and diagnosis.
High-quality prognostic genes, including CDC20, ASPM, CDCA8, SGOL1, and ERCC6L, play roles in G2/M processes, such as the spindle assembly checkpoint. 31,32,38,39 Therefore, the regulation of anaphase of the cell cycle is intimately associated with patient survival.
Thirdly, we associated the mutations and the prognostic genes. Mutations in the PI3K-AKT, ErbB, and FoxO signaling pathways, and in the biological processes of tight junction and methylation, can ubiquitously alter the expression of the prognostic genes. Further relationships were seen between prognostic genes that function in anaphase of the cell cycle, especially CDC20, CDCA8, ASPM and GTSE1, and the mutated genes including TP53, PTEN, ATM, EP400 and BAI3. PKHD1 mutations link seven prognostic genes (Fig. 5B) . Fibrocystin, encoded by PKHD1 in the liver and kidney, may be involved in cell adhesion, cell repulsion, and the growth and division of cells.
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Our results provide a comprehensive prognostic and diagnostic gene list, and reveal the characteristics of prognostic genes of cancer and the statistical association to mutation.
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Materials and methods
Datasets
Gene expression data, survival data, and mutation data used in this study were retrieved from TCGA project from the initial release of Genomic Data Commons (GDC) in October 2016 (https://portal.gdc.cancer.gov/) using RTCGAToolbox.
1 A total of 9523 samples across 29 tumor types were downloaded, including 8811 tumor tissues and 712 non-tumor tissues.
Microarray-based gene expression data (gene expression omnibus ID: GSE21501 for pancreatic cancer 2 ) were retrieved for validating the expression markers for survival.
Identification of the prognostic genes
Genes whose expression is associated with a differential overall survival were identified with a log-rank test in a Kaplan-Meier survival model. In each cancer type, for each gene, patients were classified into two groups using the expression median of the gene as a cutoff. The two groups were named the high-expression group (H) and the low-expression group (L), depending on whether the expression level was higher or lower than the median, respectively.
The survival difference was tested in the two groups. In identifying, we considered both survival difference and the expression change between the two groups. First, the criteria of a We investigated the relationship between the mutation counts and the survival time. The survival time was truncated at a survival probability of 60%. We also tested the relationship between the normalized mutation rate and the expression level.
Regression for the expression of the prognostic genes with the mutation counts
The 40 prognostic genes, which were identified with P The regression generated a set of parameters indicating the contribution of the mutation in explaining the expression level of the prognostic gene. Only mutated genes with a significant parameter were used to construct a network.
Enrichment analysis
The enrichment analysis for the 236 prognostic genes and the top 200 frequently mutated genes was carried out with DAVID. 
Other analysis in the work
The activation status of pathways was assessed with SPIA. 8 D. An enrichment analysis for the top 200 genes ranked by the normalized maximum mutation rate.
E. An enrichment analysis for the top 200 genes whose mutations associate to the shortest survivals (from Fig. S6C ).
Supplementary Files
Suppl-1
The prognostic genes identified at criteria of P[SV]10 3 and FC(H/L)2, selecting the top ten genes for each cancer type. There were a total of 236 genes in 29 cancer types. Here, in each cancer type, for each gene, patients are classified into high (H) and low (L) expression groups using the expression median of the gene as a cutoff. The survival difference (P[SV]) was tested between the two groups with a log-rank test. FC(H/L) means the fold change of average expression between the two groups. In the files, chi-square is the value of  2 in the log-rank test, T-middle-H and T-middle-L are the time at 50% survival probability for the high-and low-expression groups, respectively, and mean-H and mean-L are the mean expression in the high-and low-expression groups, respectively. The gene symbol and cell type are the official symbol of the prognostic gene and the corresponding cancer type, respectively.
Suppl-2
The prognostic genes identified at criteria of P 
Suppl-3
The 
Suppl-4
The programs (in Matlab) that used in the analysis; "Survival_Analysis_OKAY.m", for survival analysis based on Kaplan-Meier survival model. "SR_chi_test_bigdata.m", for survival difference test, namely log-rank test.
"plot_Survival_Anlysis", for plotting the survival curves. The top 200 genes ranked by the normalized maximum mutation rate
The top 200 genes whose mutations associate to the shortest survival time
